BioSpace News Archive

Oligomerix, Inc. announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer’s Disease

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), today announced the publication of abstracts with clinical data for Iovance tumor-infiltrating lymphocyte (TIL) therapy in combination with pembrolizumab in patients with advanced cancers and for Iovance TIL cell therapy in relapsed, refractory lung cancer.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), today reported financial results for the third quarter ended September 30, 2021 and provided recent corporate updates.

Arkstone Medical Solutions, the leading provider of proactive antimicrobial stewardship, is pleased to announce the appointment of Dr. Juan Carlos Gómez de la Torre Pretell as their new Director of Molecular Informatics.

SYNAPS Dx (SDx), announces that DISCERN™, the first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of AD versus other forms of non-AD dementias and those with AD and other degenerative pathologies, is the first AD test of its kind to earn Proprietary Laboratory Analyses (PLA) Code 206U and 207U.

Seagen Inc. (Nasdaq:SGEN), today announced the presentation of two new vedotin-based antibody-drug conjugate (ADC) programs at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, taking place in Washington, D.C. and virtually, November 10-14, 2021.

Paris– November9, 2021 - Sanofi announced the completion of its acquisition of Kadmon Holdings, Inc.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 15, 2021 to discuss financial results for third quarter ended September 30, 2021.

Fate Therapeutics, Inc. (NASDAQ: FATE), today announced that the Society for Immunotherapy of Cancer (SITC) Communications Committee selected an abstract featuring preclinical data from the Company’s FT538 and FT573 programs for showcase at the SITC 2021 Annual Meeting Press Conference.

AXIM Biotechnologies, Inc, an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced their publication in the Journal of Clinical Virology describing the development of a rapid test to measure levels of neutralizing antibodies to SARS-CoV-2.